Charles Reay Mackay joins Pfizer
This article was originally published in Scrip
Pfizer has named Charles Reay Mackay chief scientific officer for its inflammation and immunology research unit. Professor Mackay will report directly to José-Carlos Gutiérrez-Ramos, group vice-president of BioTherapeutics R&D, and will be based in Pfizer's R&D hub in Cambridge, Massachusetts. Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was chair of diabetes. Inflammation and immunology is one of Pfizer's key therapeutic areas.
You may also be interested in...
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Emerging Company Profile: Irish start-up Shorla Pharma recently secured $8.3m to move its pipeline candidates into the clinic. While it is not the largest series A financing for an emerging biotech, the company expects to get its first “re-innovated” product approved in the US next year.
Infographic: As the novel coronavirus continues to cause disruption and leave casualties across the globe, In Vivo has taken a look at the activities of the life sciences sector in response. Here is a breakdown of biopharma and medtech research actions against COVID-19.